Alzamend Neuro Statistics
Total Valuation
Alzamend Neuro has a market cap or net worth of $2.97 million. The enterprise value is $2.69 million.
| Market Cap | 2.97M |
| Enterprise Value | 2.69M |
Important Dates
The next estimated earnings date is Monday, July 29, 2024, before market open.
| Earnings Date | Jul 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Alzamend Neuro has 798,176 shares outstanding. The number of shares has increased by 7.62% in one year.
| Shares Outstanding | 798,176 |
| Shares Change (YoY) | +7.62% |
| Shares Change (QoQ) | +7.47% |
| Owned by Insiders (%) | 25.53% |
| Owned by Institutions (%) | 4.85% |
| Float | 569,337 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.16
| Current Ratio | 0.16 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,353.94 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -481.20% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.77M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.24% in the last 52 weeks. The beta is 0.03, so Alzamend Neuro's price volatility has been lower than the market average.
| Beta (5Y) | 0.03 |
| 52-Week Price Change | -95.24% |
| 50-Day Moving Average | 4.97 |
| 200-Day Moving Average | 10.76 |
| Relative Strength Index (RSI) | 36.91 |
| Average Volume (20 Days) | 11,025 |
Short Selling Information
The latest short interest is 29,939, so 3.75% of the outstanding shares have been sold short.
| Short Interest | 29,939 |
| Short Previous Month | 95,079 |
| Short % of Shares Out | 3.75% |
| Short % of Float | 5.26% |
| Short Ratio (days to cover) | 0.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.39M |
| Pretax Income | -12.40M |
| Net Income | -12.40M |
| EBITDA | -12.35M |
| EBIT | -12.39M |
| Earnings Per Share (EPS) | -$18.70 |
Balance Sheet
The company has $282,867 in cash and no debt, giving a net cash position of $282,867 or $0.35 per share.
| Cash & Cash Equivalents | 282,867 |
| Total Debt | n/a |
| Net Cash | 282,867 |
| Net Cash Per Share | $0.35 |
| Equity (Book Value) | -4.26M |
| Book Value Per Share | -5.34 |
| Working Capital | -3.23M |
Cash Flow
In the last 12 months, operating cash flow was -$9.08 million and capital expenditures -$147,243, giving a free cash flow of -$9.23 million.
| Operating Cash Flow | -9.08M |
| Capital Expenditures | -147,243 |
| Free Cash Flow | -9.23M |
| FCF Per Share | -$13.08 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Alzamend Neuro does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.62% |
| Shareholder Yield | -7.62% |
| Earnings Yield | -417.68% |
| FCF Yield | -310.71% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 16, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |